Enhancement of oral bioavailability of phenytoin by esterification, and in vitro hydrolytic characteristics of prodrugs

International Journal of Pharmaceutics

Volumn 163, Issue 1-2, 1998, Pages 91-102

  Tanino, Tadatoshi ^a   Ogiso, Taro ^a   Iwaki, Masahiro ^a   Tanabe, Genzou ^a   Muraoka, Osamu ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

Enzymatic hydrolysis; Esteric prodrug; Oral bioavailability; Phenytoin; Rat

Indexed keywords

ANTICONVULSIVE AGENT; N CARBOETHOXYPHENYTOIN; N CARBOISOPROPOXYPHENYTOIN; PHENYTOIN; PHENYTOIN DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SYNTHESIS; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

EID: 0032542789     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00374-8     Document Type: Article

References (35)

1. Arnold K., Gerber N. The rate of decline of diphenylhydantoin in human plasma. Clin. Pharmacol. Ther. 11:1970;121-134.
2. Arnold K., Gerber N., Levy G. Absorption and dissolution studies on sodium diphenylhydantoin capsules. Can. J. Pharm. Sci. 5:1970;89-92.
3. Badir K., Haj-Yehia A., Vree T.B., van der Kleijn E., Bialer M. Pharmacokinetics and anticonvulsant activity of three monoesteric prodrugs of valproic acid. Pharm. Res. 8(6):1991;750-753.
4. Baldessarini R.J., Kula N.S., Walton K.G., Borgman R. Hydrolysis of diester prodrugs of apomorphine. J. Biochem. Pharmacol. 26:1977;1749-1756.
5. Bansal P.C., Pitman I.H., Tam J.N.S., Mertes M., Kaminski J.J. N-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs I: N-hydroxymethylation of uracils. J. Pharm. Sci. 70:1981;850-854.
6. Bansal P.C., Pitman I.H., Higuchi T. N-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs II: possible prodrugs of allopurinol, glutethimide and phenobarbital. J. Pharm. Sci. 70:1981;855-857.
7. Bialer M., Friedman M., Dubrovsky J., Raz I., Abramsky O. Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans. Biopharm. Drug Dispos. 6:1985;401-411.
8. Borondy P., Chang T., Glazko A. Inhibitor of DPH hydroxylation by 5-(p-hydroxyphenyl)-5-phenylhydantoin (p-HPPH). J. Fed. Proc. 31:1972;582.
9. Buchthal, F., 1972. M.A. Lennox-Buchthal in antiepileptic drugs. In: Woodbury, D.M., Penry, J.K., Schmidt, R.P. (Eds.), Raven, New York, pp. 193-209.
10. Colburn W.A., Gibaldi M. Plasma protein binding and metabolic clearance of DPH in the rat. J. Pharmacol. Exp. Ther. 203(3):1977;500-506.
11. Gerber N., Weller W.L., Lynn R., Rangno R.E., Sweetman B.J., Bush M.T. Study of dose-dependent metabolism of 5,5- diphenylhydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro. J. Pharmacol. Exp. Ther. 178:1971;567-579.
12. Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, pp. 84; idem, ibid, p. 409.
13. Gibaldi, M., Perrier, D., 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, New York, pp. 84; idem, ibid, p. 409.
14. Hadad S., Vree T.B., van der Kleijn E., Bialer M. Pharmacokinetic analysis of ester prodrugs of valproic acid. J. Pharm. Sci. 81(10):1992;1047-1050.
15. Lambert D.M., Masereel B., Gallez B., Geurts M., Scriba G.K.E. Bioavailability and anticonvulsant activity of 2-cyanoguanidino DPH, a structural analogue of DPH. J. Pharm. Sci. 85(10):1996;1077-1081.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
17. Merritt M.H., Putnam J.T. Sodium diphenylhydantoinate in treatment of convulsive disorders. J. Am. Med. Assoc. 111:1938;1068-1073.
18. Nakamura K., O'Hashi K., Nakatsuji K., Hiroka T., Fujimoto K., Ose S. The anticonvulsant activity of 3-ethoxycarbonyl-5,5-diphenylhydantoin (P-6127) in animals. Arch. Int. Pharmacodyn. 156(2):1965;261-270.
19. Nakamura H., Nakatsuji K., Kadokawa T., Nakamura K. Pharmacological studies of a new anti-inflammatory drug, 1-phenylsulfonyl-5,5-diphenylhydantoin (PC-796) in experimental animals. Arzneim-Forsch. 20:1970;1032-1046.
20. Ogiso T., Iwaki M., Tanino T., Muraoka O., Tanabe G. Pharmacokinetic analysis of DPH and its derivatives in plasma and brain in rats. Biol. Pharm. Bull. 16(10):1993;1025-1030.
21. Ogiso T., Tanino T., Iwaki M., Muraoka O., Tanabe G. Physicochemical and hydrolytic characteristics of DPH derivatives. Biol. Pharm. Bull. 17(10):1994;1425-1429.
22. Pop E., Shek E., Murakami T., Bodor N. Improved anticonvulsant activity of DPH by a redox brain delivery system I: synthesis and some properties of the diphydropyridine derivatives. J. Pharm. Sci. 78(8):1986;609-616.
23. Scriba G.K.E. DPH-lipid conjugates as potential prodrugs of DPH. Arch. Pharm. 327:1994;347-348.
24. Scriba G.K.A., Lambert D.M., Poupaert J.H. Anticonvulsant activity of DPH-lipid conjugates, a new class of DPH prodrugs. J. Pharm. Pharmacol. 47:1995;197-203.
25. Scriba G.K.A., Lambert D.M., Poupaert J.H. Bioavailability and anticonvulsant activity of a monoglyceride-derived prodrug of DPH after oral administration to rats. J. Pharm. Sci. 84:1995;300-302.
26. Scriba G.K.A., Lambert D.M., Poupaert J.H. Bioavailability of DPH following oral administration of DPH-lipid conjugations to rats. J. Pharm. Pharmacol. 47:1995;945-948.
27. Sekikawa H., Fujiwara J., Naganuma T., Nakano M., Arita T. Dissolution behaviors and gastrointestinal absorption of DPH in DPH-polyvinylpyrrolidone coprecipitate. Chem. Pharm. Bull. 26:1978;3033-3039.
28. Stella V.J., Charman W.N.A., Naringrekar V.H. Prodrugs: do they have advantages in clinical practice? Drugs. 29:1985;455-473.
29. Suzuki S., Miyazaki Y., Sakurai S., Yakou S., Sugihara M. Dissolution behavior of DPH solid dispersion. Yakuzaigaku. 50:1990;273-278.
30. Sugiyama T., Yamamoto A., Kawabe K., Uchiyama T., Quan Ying-Shu, Muranishi S. Effect of various absorption enhancers on the intestinal absorption of water-soluble drugs by in vitro using chamber method: correlation with an in situ absorption experiment. Biol. Pharm. Bull. 20(7):1997;812-814.
31. Upton R.A. Simple and reliable method for serial sampling of blood from rats. J. Pharm. Sci. 64:1975;112-114.
32. Varia S.A., Stella V.J. DPH prodrugs VI: in vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J. Pharm. Sci. 73(8):1984;1087-1090.
33. Varia S.A., Schuller S., Sloan K.B., Stella V.J. DPH prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J. Pharm. Sci. 73(8):1984;1068-1073.
34. Yakou S., Yamazaki S., Sonobe T., Nagai T., Sugihara M. Dissolution and bioavailability of DPH in DPH-polyvinylpyrrolidone-sodium deoxycholate coprecipitate. Chem. Pharm. Bull. 34:1986;3408-3414.
35. Yamaoka K., Tanigawara T., Nakagawa T., Uno T. Pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4:1981;879-885.